DSPE-PEG2000-MAL£º¸³ÄÜin vivo CAR-TµÝË͵ÄÐÂ×¥ÊÖ-·Ç·²¹ú¼Ê,Ö§Á´¾ÛÒÒ¶þ´¼ÑÜÉúÎï,Ö±Á´¾ÛÒÒ¶þ´¼ÑÜÉúÎï"> ·Ç·²¹ú¼Ê,Ö§Á´¾ÛÒÒ¶þ´¼ÑÜÉúÎï,Ö±Á´¾ÛÒÒ¶þ´¼ÑÜÉúÎï ·Ç·²¹ú¼ÊÊÇ2001Äê10ÔÂ×¢²á½¨ÉèµÄÖÂÁ¦ÓÚÒ½ÓÃÒ©ÓþÛÒÒ¶þ´¼ÑÜÉúÎ﹤ҵ»¯µÄ¸ßÐÂÊÖÒÕÆóÒµ£¬ £¬£¬£¬£¬£¬£¬£¬×¢²áÓÚ±±¾©Êк£µíÇø¡£ ¡£¡£¡£¡£¡£¡£¡£"> ·Ç·²¹ú¼Ê,Ö§Á´¾ÛÒÒ¶þ´¼ÑÜÉúÎï,Ö±Á´¾ÛÒÒ¶þ´¼ÑÜÉúÎï"> DSPE-PEG2000-MAL£º¸³ÄÜin vivo CAR-TµÝË͵ÄÐÂ×¥ÊÖ-·Ç·²¹ú¼Ê,Ö§Á´¾ÛÒÒ¶þ´¼ÑÜÉúÎï,Ö±Á´¾ÛÒÒ¶þ´¼ÑÜÉúÎï"> ·Ç·²¹ú¼Ê,Ö§Á´¾ÛÒÒ¶þ´¼ÑÜÉúÎï,Ö±Á´¾ÛÒÒ¶þ´¼ÑÜÉúÎï ·Ç·²¹ú¼ÊÊÇ2001Äê10ÔÂ×¢²á½¨ÉèµÄÖÂÁ¦ÓÚÒ½ÓÃÒ©ÓþÛÒÒ¶þ´¼ÑÜÉúÎ﹤ҵ»¯µÄ¸ßÐÂÊÖÒÕÆóÒµ£¬ £¬£¬£¬£¬£¬£¬£¬×¢²áÓÚ±±¾©Êк£µíÇø¡£ ¡£¡£¡£¡£¡£¡£¡£">

·Ç·²¹ú¼Ê

DSPE-PEG2000-MAL£º¸³ÄÜin vivo CAR-TµÝË͵ÄÐÂ×¥ÊÖ

2025-11-04

×ÖºÅ

¡¡¡¡CAR-TÁÆ·¨ÊÇÈËÀàÔÚÉúÎïÒ½Ò©ÁìÓò¼ÌС·Ö×Ó¡¢´ó·Ö×ÓÒÔºó£¬ £¬£¬£¬£¬£¬£¬£¬ÔÚϸ°û²ãÃæÈ¡µÃµÄÓÖÒ»´Î¸ïÃüÐÔÍ»ÆÆ¡£ ¡£¡£¡£¡£¡£¡£¡£ÌåÍâCAR-T(ex vivo CAR-T)ÒÑÔÚBϸ°û°×Ѫ²¡ºÍÁÜ°ÍÁö´´ÏÂÁËѤÀõÄÀï³Ì±®£¬ £¬£¬£¬£¬£¬£¬£¬µ«ÆäÖØ´óµÄÖÆÔìÀú³Ì¡¢¸ß°ºµÄÓöȼ°¶¾ÐԵȾÖÏÞ³ÉΪÁËÕâÏîÊÖÒÕ´óÃæ»ýÆÕ¼°µÄÆ¿¾±ËùÔÚ¡£ ¡£¡£¡£¡£¡£¡£¡£¶øÌåÄÚCART(in vivo CAR-T)ÔòÒÔÇ㸲ÐÔµÄÊÖÒÕ£¬ £¬£¬£¬£¬£¬£¬£¬Í¨¹ýÌØÊâÔØÌ彫CAR»ùÒòÖ±½ÓËÍÈëÌåÄÚ£¬ £¬£¬£¬£¬£¬£¬£¬Ìø¹ý·±ËöµÄÌåÍâ°ì·¨£¬ £¬£¬£¬£¬£¬£¬£¬Ö±½ÓÔÚ»¼ÕßÌåÄÚÍê³É¶ÔTϸ°ûµÄ“×°±¸Éý¼¶”£¬ £¬£¬£¬£¬£¬£¬£¬³ÉΪÏÂÒ»´úϸ°ûÃâÒßÖÎÁƵÄÆƾֵ㡣 ¡£¡£¡£¡£¡£¡£¡£

¡¡¡¡2025Äê6ÔÂ11ÈÕ£¬ £¬£¬£¬£¬£¬£¬£¬ÔËÓÃLNPΪÖ÷ÒªµÝËÍÔØÌåµÄin vivo CAR-TÁÆ·¨¹«Ë¾CapstanÐû²¼£¬ £¬£¬£¬£¬£¬£¬£¬ÆäÒÔרÓÐÊÖÒÕtLNP(ÌåÄÚ°ÐÏòÖ¬ÖÊÄÉÃ׿ÅÁ£)ΪÔØÌåµÄin vivo CAR-Tϸ°ûÁÆ·¨CPTX2309Õýʽ×îÏÈ¢ñÆÚÁÙ´²ÊÔÑ飬 £¬£¬£¬£¬£¬£¬£¬ÓÃÓÚÖÎÁÆBϸ°û½éµ¼µÄ×ÔÉíÃâÒß¼²²¡1¡£ ¡£¡£¡£¡£¡£¡£¡£Ëæºó£¬ £¬£¬£¬£¬£¬£¬£¬2025Äê6ÔÂ30ÈÕ£¬ £¬£¬£¬£¬£¬£¬£¬°¬²®Î¬ÓëCapstanÐû¹«¸æ¿¢×îÖÕЭÒ飬 £¬£¬£¬£¬£¬£¬£¬°¬²®Î¬½«ÒÔ21ÒÚÃÀÔªµÄ¼ÛÇ®ÊÕ¹ºCapstan£¬ £¬£¬£¬£¬£¬£¬£¬´Ë´ÎÊÕ¹ºº­¸ÇÆä¸Õ½øÈë¢ñÆÚÁÙ´²ÊÔÑéµÄCPTX23092¡£ ¡£¡£¡£¡£¡£¡£¡£Í¬Ê±£¬ £¬£¬£¬£¬£¬£¬£¬°¬²®Î¬»¹½«»ñµÃCapstanµÄtLNPƽ̨ÊÖÒÕ£¬ £¬£¬£¬£¬£¬£¬£¬¸ÃÊÖÒÕÖ¼ÔÚµÝËÍRNAÓÐÓÃÔغÉ(ÈçmRNA)£¬ £¬£¬£¬£¬£¬£¬£¬Äܹ»ÔÚÌåÄÚ¶ÔÌض¨Ï¸°ûÀàÐ;ÙÐй¤³ÌˢС£ ¡£¡£¡£¡£¡£¡£¡£

¡¡¡¡ÄÉÃ×ÊÖÒյķÉËÙÉú³¤ÎªÒ©ÎïµÝËÍϵͳ´øÀ´Á˸ïÃüÐÔµÄÍ»ÆÆ¡£ ¡£¡£¡£¡£¡£¡£¡£ÒÔCapstanµÄÊÖÒÕƽ̨ΪÀý£¬ £¬£¬£¬£¬£¬£¬£¬ÔÚÖƱ¸LNPʱ»ìÈëÒÔÂíÀ´õ£ÑÇ°·»ùÍÅ(-Maleimide£¬ £¬£¬£¬£¬£¬£¬£¬MAL)µÄPEGÖ¬£¬ £¬£¬£¬£¬£¬£¬£¬´ýLNPÖƱ¸Íê³Éºó£¬ £¬£¬£¬£¬£¬£¬£¬ÔÙ½«´øÓÐÛÏ»ù(-SH)µÄ¿¹Ìåͨ¹ý·õÓýµÄ·½·¨Å¼ÁªÔÚº¬ÓÐMAL»ùÍŵÄPEGÖ¬ÉÏ£¬ £¬£¬£¬£¬£¬£¬£¬¼´¿É¸¶ÓëLNPϵͳ“×Ô¶¯°ÐÏò”µÄÄÜÁ¦¡£ ¡£¡£¡£¡£¡£¡£¡£

¡¡¡¡DSPE-PEG2000-MAL(1,2-¶þÓ²Ö¬õ£-sn-¸ÊÓÍ-3-Á×ËáÒÒ´¼°·-¾ÛÒÒ¶þ´¼2000-ÂíÀ´õ£ÑÇ°·)×÷ΪһÖÖÉè¼Æ¾«ÇɵĹ¦Ð§»¯Á×Ö¬-PEGÑÜÉúÎ £¬£¬£¬£¬£¬£¬£¬ÒѳÉΪ¹¹½¨ÏȽøÄ˽×ÔØÌåµÄÖ÷ÒªÁ¢ÒìÖÊÁÏÖ®Ò»¡£ ¡£¡£¡£¡£¡£¡£¡£ÆäÆæÒìµÄ·Ö×ӽṹ¸¶ÓëÁËÔØÌ峤ѭ»·¡¢×Ô¶¯°ÐÏò¼°¶à¹¦Ð§¼¯³É»¯µÄÄÜÁ¦£¬ £¬£¬£¬£¬£¬£¬£¬ÔÚ°ÐÏòÖÎÁÆ¡¢·Ö×ÓÓ°ÏñºÍÃâÒßÁÆ·¨µÈÁìÓòÕ¹ÏÖ³öÖØ´óµÄÓ¦ÓÃDZÁ¦¡£ ¡£¡£¡£¡£¡£¡£¡£

¡¡¡¡·Ö×ӽṹÓëÀí»¯ÌØÕ÷

¡¡¡¡DSPE-PEG2000-MALµÄ·Ö×ÓÁ¿Ô¼Îª2805–3000Da£¬ £¬£¬£¬£¬£¬£¬£¬Ö÷Òª°üÀ¨Èý¸ö¹¦Ð§Ã÷È·µÄÄ£¿£¿£¿£¿£¿£¿£¿£¿é£º

¡¡¡¡DSPE(1,2-Distearoyl-sn-glycero-3-phosphoethanolamine)Êèˮ궨»ùÍÅ£º×÷ΪÁ½Ç×ÐÔ·Ö×ÓµÄÊèˮβ²¿£¬ £¬£¬£¬£¬£¬£¬£¬DSPEº¬ÓÐÁ½ÌõC18±¥ºÍÖ¬·¾ËáÁ´£¬ £¬£¬£¬£¬£¬£¬£¬Æä½á¹¹Óëϸ°ûĤÁ×֬˫·Ö×Ó²ã¾ßÓи߶ÈÇ׺ÍÐÔ£¬ £¬£¬£¬£¬£¬£¬£¬Äܹ»Îȹ̵ØǶÈëÖ¬ÖÊÌåĤ»ò×é³É½ºÊøµÄÊèË®Äںˣ¬ £¬£¬£¬£¬£¬£¬£¬ÎªÕû¸ö·Ö×ÓÌṩÀο¿µÄ궨×÷Óᣠ¡£¡£¡£¡£¡£¡£¡£

¡¡¡¡PEG2000(Polyethyleneglycol)Ç×Ë®Á´¶Î£º·Ö×ÓÁ¿Ô¼Îª2000DaµÄ¾ÛÒÒ¶þ´¼Á´×é³ÉÁË·Ö×ÓµÄÇ×Ë®¹Ú²ã¡£ ¡£¡£¡£¡£¡£¡£¡£ÔÚÐÄÀíÇéÐÎÖУ¬ £¬£¬£¬£¬£¬£¬£¬PEGÁ´Í¨¹ý¿Õ¼äλ×èЧӦºÍË®ºÏ×÷Ó㬠£¬£¬£¬£¬£¬£¬£¬ÔÚÄ˽×ÔØÌåÍâòÐγÉÒ»²ãÖÂÃܵēˮ»¯ÔÆ”£¬ £¬£¬£¬£¬£¬£¬£¬ÓÐÓÃïÔ̭Ѫ½¬ÂÑ°×µÄÎü¸½£¬ £¬£¬£¬£¬£¬£¬£¬´Ó¶ø¹æ±ÜÍø×´ÄÚƤϵͳµÄ¿ìËÙɨ³ý¡£ ¡£¡£¡£¡£¡£¡£¡£ÕâÒ»ÌØÕ÷£¬ £¬£¬£¬£¬£¬£¬£¬¼´“ÒþÐÎЧӦ”(Stealth®effect)£¬ £¬£¬£¬£¬£¬£¬£¬ÊÇÑÓÉìÔØÌåÌåÄÚÑ­»·°ëË¥ÆÚµÄÒªº¦¡£ ¡£¡£¡£¡£¡£¡£¡£

¡¡¡¡MAL(Maleimide)»îÐÔ×îºó»ùÍÅ£ºÂíÀ´õ£ÑÇ°·»ùÍÅÊÇ·Ö×ӵķ´Ó¦»îÐÔÖÐÐÄ¡£ ¡£¡£¡£¡£¡£¡£¡£ËüÄÜÔÚpH6.5-7.2µÄÌõ¼þÏ£¬ £¬£¬£¬£¬£¬£¬£¬ÓëÛÏ»ù(-SH£¬ £¬£¬£¬£¬£¬£¬£¬Áò´¼)±¬·¢¸ßЧ¡¢ÌØÒìÐÔµÄÂõ¿Ë¶û¼Ó³É·´Ó¦£¬ £¬£¬£¬£¬£¬£¬£¬ÐγÉÎȹ̵ÄÁòÃѹ²¼Û¼ü¡£ ¡£¡£¡£¡£¡£¡£¡£ÕâÒ»»¯Ñ§Ñ¡ÔñÐÔʹÆä³ÉΪÅþÁ¬º¬°ëë×°±Ëá²Ð»ùµÄ°ÐÏòÅäÌå(È翹Ìå¡¢¶àëÄ¡¢ÊÊÅäÌå)µÄÀíÏë“»¯Ñ§×¥ÊÖ”¡£ ¡£¡£¡£¡£¡£¡£¡£

       

ÏîÄ¿ ÐÎò
Íâ¹Û °×É«»òÀà°×É«À¯×´¹ÌÌå
ÏûÈÚÐÔ ¿ÉÔÚDMSO¡¢ÒÒ´¼¡¢ÎÂË®ÖÐÊèÉ¢»òÏûÈÚ
pHÎȹÌÐÔ pH 6.5-7.2½ÏÎȹ̣¨×èÖ¹MaleimideË®½â£©
Ó¦Óà ֬ÖÊÌåÐÞÊΡ¢ÉúÎïżÁª¡¢°ÐÏòµÝË͵È

       ÔÚʹÓÃDSPE-PEG2000-MALµÄµÝËÍϵͳÖУ¬ £¬£¬£¬£¬£¬£¬£¬DSPE¶Ë²åÈëÁ×֬˫·Ö×Ӳ㣬 £¬£¬£¬£¬£¬£¬£¬PEGÁ´ÑÓÉìÖÁÍⲿˮÏ࣬ £¬£¬£¬£¬£¬£¬£¬ÏÔÖøÌáÉýÁËϵͳµÄÎȹÌÐÔºÍÌåÄÚÑ­»·¶¯Á¦Ñ§¡£ ¡£¡£¡£¡£¡£¡£¡£ÀýÈ磬 £¬£¬£¬£¬£¬£¬£¬¾­PEGÐÞÊεÄÖ¬ÖÊÌå(ÈçDoxil®)°ëË¥ÆÚ¿É´ÓÊýСʱÑÓÉìÖÁÔ¼55Сʱ£¬ £¬£¬£¬£¬£¬£¬£¬²¢½èÖúÔöÇ¿Éø͸ÖÍÁôЧӦÔÚÖ×Áö²¿Î»ÊµÏÖ±»¶¯¸»¼¯3¡£ ¡£¡£¡£¡£¡£¡£¡£¶øMAL»ùÍÅÄÜÓ뺬ÛÏ»ù(-SH)·Ö×Ó¶¨ÏòżÁªµÄÌØÕ÷£¬ £¬£¬£¬£¬£¬£¬£¬¸¶ÓëÆä“×Ô¶¯°ÐÏò”µÄÄÜÁ¦¡£ ¡£¡£¡£¡£¡£¡£¡£ÔÚ½ºÊøϵͳÖУ¬ £¬£¬£¬£¬£¬£¬£¬DSPE-PEG2000-MALÒ²¿É×Ô×é×°ÐγɺË-¿Ç½á¹¹£¬ £¬£¬£¬£¬£¬£¬£¬ÊèË®µÄDSPEÄÚºËÓÃÓÚÔöÈÜ×Ïɼ´¼µÈÄÑÈÜÐÔ»¯ÁÆÒ©Î £¬£¬£¬£¬£¬£¬£¬¶øPEGÍâ¿ÇºÍMAL¹¦Ð§»¯ÍâòÔòͬÑùÌṩÎȹÌÐÔºÍ×Ô¶¯°ÐÏòµÄDZÁ¦£¬ £¬£¬£¬£¬£¬£¬£¬ÍØÕ¹mRNAÒ©ÎïµÄÓ¦ÓùæÄ££¬ £¬£¬£¬£¬£¬£¬£¬ÊµÏÖ¸ü¾«×¼µÄϸ°ûÀàÐÍÌØÒìÐÔµÝËÍ¡£ ¡£¡£¡£¡£¡£¡£¡£

¡¡¡¡DSPE-PEG2000-MALÒÀ¸½Æä“궨-ÒþÐÎ-ÅþÁ¬”ÈýλһÌåµÄ·Ö×ÓÉè¼Æ£¬ £¬£¬£¬£¬£¬£¬£¬ÒѳÉΪ¾«×¼Ò©ÎïµÝËÍÁìÓò²»¿É»òȱµÄ¹¦Ð§ÖÊÁÏ¡£ ¡£¡£¡£¡£¡£¡£¡£Ëü²»µ«½â¾öÁËÄ˽×ÔØÌåÔÚÌåÄÚµÄÎȹÌÐԺͳ¤Ñ­»·ÎÊÌ⣬ £¬£¬£¬£¬£¬£¬£¬¸üÖ÷ÒªµÄÊÇ£¬ £¬£¬£¬£¬£¬£¬£¬Í¨¹ýÆä¸ß¶ÈÌØÒìÐԵĻ¯Ñ§Å¼ÁªÄÜÁ¦£¬ £¬£¬£¬£¬£¬£¬£¬ÊµÏÖÁ˶ÔÄ˽×ÔØÌåµÄÍâò¹¦Ð§»¯£¬ £¬£¬£¬£¬£¬£¬£¬´Ó¶ø¸¶ÓëÆä×Ô¶¯°ÐÏò¡¢ÖÇÄÜÏìÓ¦ºÍÕïÁÆÒ»Ì廯µÈ¸ß¼¶¹¦Ð§¡£ ¡£¡£¡£¡£¡£¡£¡£Ëæ×ŶÔÃâÒßÉúÎïѧ»úÖƵÄÉîÈë̽Ë÷£¬ £¬£¬£¬£¬£¬£¬£¬DSPE-PEG2000-MAL¼°ÆäÑÜÉúÎｫ¼ÌÐø×÷Ϊ¹¹½¨Öش󡢸ßЧ¡¢ÖÇÄÜÄÉÃ×Ò©ÎïϵͳµÄÖ÷Òª»ùʯ֮һ£¬ £¬£¬£¬£¬£¬£¬£¬Îª¹¥¿ËÖØ´ó¼²²¡ÖÎÁÆÖеÄÖÖÖÖÌôÕ½ÌṩǿÓÐÁ¦µÄÊÖÒÕÖ§³Ö£¬ £¬£¬£¬£¬£¬£¬£¬Íƶ¯¾«×¼Ò½ÁÆÂõÏòеĸ߶ȡ£ ¡£¡£¡£¡£¡£¡£¡£

¡¡¡¡×÷ΪרעÓÚÒ©ÎïµÝËÍÊÖÒÕµÄÁ¢ÒìÐÍÆóÒµ£¬ £¬£¬£¬£¬£¬£¬£¬·Ç·²¹ú¼Ê¿Æ¼¼³Ð¼Ì“ÒÔÖÊÁÏÁ¢ÒìÒýÁìÉúÎïÒ½Ò©Á¢Ò쓵Ä×ÚÖ¼£¬ £¬£¬£¬£¬£¬£¬£¬ÒÀÍÐ×ÔÉíÔÚÒ©ÎïµÝËÍÁìÓòµÄÖÕÄê»ýÀÛÓëÁ¢ÒìÓÅÊÆ£¬ £¬£¬£¬£¬£¬£¬£¬¿ÉΪÄúÌṩÇкÏÑз¢¼°ÖÐÍâÉ걨ÐèÇóµÄDSPE-PEG2000-MAL²úÆ·£¬ £¬£¬£¬£¬£¬£¬£¬²¢ÎªÈ«ÇòºÏ×÷»ï°éÔÚºóÐøµÄÑо¿ÓëÓ¦ÓÃÀú³ÌÖУ¬ £¬£¬£¬£¬£¬£¬£¬ÌṩÒÔÇ°ÆÚÑз¢µ½ºóÆÚת»¯µÄÈ«Á÷³ÌÖ§³Ö¡£ ¡£¡£¡£¡£¡£¡£¡£

¡¡¡¡²Î¿¼ÎÄÏ×

¡¡¡¡1 WIRE, B. Capstan Therapeutics Announces Initiation of Phase 1 Trial of Lead In Vivo CAR-T Therapy, CPTX2309, for Treating Autoimmune Disease, <https://www.businesswire.com/news/home/20250611668181/en/Capstan-Therapeutics-Announces-Initiation-of-Phase-1-Trial-of-Lead-In-Vivo-CAR-T-Therapy-CPTX2309-for-Treating-Autoimmune-Disease> (2025).

¡¡¡¡2 AbbVie. AbbVie to Acquire Capstan Therapeutics, Further Strengthening Commitment to Transforming Patient Care in Immunology, <https://news.abbvie.com/2025-06-30-AbbVie-to-Acquire-Capstan-Therapeutics,-Further-Strengthening-Commitment-to-Transforming-Patient-Care-in-Immunology> (2025).

¡¡¡¡3 Gabizon, A. et al. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res 54, 987-992 (1994).

Òªº¦´Ê£º

ÍøÕ¾µØͼ